Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : Mexico will not follow FDA in approving Gilead's COVID-19 drug

10/23/2020 | 11:03pm EST
FILE PHOTO: An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference

MEXICO CITY (Reuters) - Mexico will not necessarily follow the U.S. Food and Drug Administration (FDA) in approving Gilead Science Inc's antiviral drug remdesivir for use in COVID-19 patients, a top Mexican health official said on Friday.

Mexico's health regulator Cofepris has already twice denied approval for the drug with a "non-favorable" opinion, deputy health minister Hugo Lopez-Gatell told his regular nightly news conference.

"We have no mandate from the FDA," he said. "Cofepris has identified that the evidence does not suggest a usefulness, a sufficient efficacy."

The FDA approved remdesivir on Thursday, making it the first and only drug approved for the disease in the United States.

Remdesivir, given intravenously, was one of the drugs used to treat U.S. President Donald Trump during his bout with COVID-19.

The World Health Organization's (WHO) Solidarity drug trial last week concluded remdesivir has little or no impact on a patient's chances of surviving COVID-19, and a top WHO scientist on Friday recommended the FDA consider all available evidence.

Lopez-Gatell said Gilead had sent a letter to doctors in Mexico refuting the results of the Solidarity trial, and that officials were looking to see if the letter could be cause for sanction, given that remdesivir is not registered with Mexican health authorities.

"It confuses the population and generates a false expectation of the possibility of having a treatment option," he said.

Gilead did not immediately respond to a request for comment.

(Reporting by Sharay Angulo and Daina Beth Solomon; Editing by Sonya Hepinstall and Tom Hogue)


© Reuters 2020
All news about GILEAD SCIENCES, INC.
12/01GILEAD SCIENCES : Canada Announces Notice of Compliance for DESCOVY® (emtricitab..
AQ
11/25EU seeks to bypass patents to boost drugs access in crises
RE
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
AQ
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
BU
11/23Canada could approve COVID-19 vaccines early next year -regulator
RE
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
RE
11/22FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
RE
11/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/20Health Care Down, But Not By Much, Amid Vaccine Optimism -- Health Care Round..
DJ
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 484x
Yield 2020 4,46%
Capitalization 76 616 M 76 616 M -
EV / Sales 2020 4,11x
EV / Sales 2021 3,92x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 61,12 $
Spread / Highest target 71,8%
Spread / Average Target 20,3%
Spread / Lowest Target -5,10%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-5.94%76 616
VERTEX PHARMACEUTICALS5.18%59 887
REGENERON PHARMACEUTICALS36.91%54 257
WUXI APPTEC CO., LTD.57.04%39 976
BIONTECH SE236.51%27 452
GENMAB A/S58.76%24 885